Diagnostic recombinant C-peptide (C-Peptide) antigens (recombinant C-peptide (C-Peptide) ) protein) for diabetes C-Peptide detection in positive control, ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.

C-peptide is a widely used measure of pancreatic beta cell function. It is produced in equimolar amounts to endogenous insulin but is excreted at a more constant rate over a longer time. Methods of estimation include urinary and unstimulated and stimulated serum sampling. Modern assays detect levels of c-peptide which can be used to guide diabetes diagnosis and management. C-peptide is a useful and widely used method of assessing pancreatic beta cell function. After cleavage of proinsulin, insulin and the 31-amino-acid peptide c-peptide are produced in equal amounts. So why is c-peptide testing preferable to insulin as a guide to beta cell function? The degradation rate of c-peptide in the body is slower than that of insulin (half-life of 20–30 min, compared with the half-life of insulin of just 3–5 min), which affords a more stable test window of fluctuating beta cell response. In healthy individuals the plasma concentration of c-peptide in the fasting state is 0.3–0.6 nmol/l, with a postprandial increase to 1–3 nmol/l. Half of all insulin secreted by the pancreas is metabolized in the liver by first-pass metabolism, whereas c-peptide has negligible hepatic clearance. C-peptide is cleared in the peripheral circulation at a constant rate, whereas insulin is cleared variably making direct measurement less consistent. In insulin-treated patients with diabetes, measurement of c-peptide also avoids the pitfall of cross-reaction of assay between exogenous and endogenous insulin.

C-peptide is a cornerstone of the assessment of non-diabetes-associated hypoglycemia and the diagnosis of conditions such as insulinoma and factitious hypoglycemia but this area is beyond the scope of this article. Increasing evidence suggests that c-peptide may also be useful in predicting future levels of glycemic control, response to hypoglycemic agents, and risk of future diabetes complications. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446389/

Genemedi produces core diagnostic ingredients for test of diabetes and related syndrome. GeneMedi offers paired diagnostics grade C-peptide (C-Peptide) antibodies (monoclonal antibody, mab) and C-peptide (C-Peptide) antigens for diabetes rapid test kit of C-peptide (C-Peptide) testing in positive control, ELISA test,Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.

All the antibodies and antigens for diabetes test are suitable for in functional ELISA, and other immunoassays in dignostics. The antibodies can act as a capture antibody and detection antibody. The antigens can be used for antibodies rapid test of diabetes.

Order information

Description